secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013486
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q2 net loss $23.9M; GM1 gene therapy shows biomarker normalization at Dose 2; cash runway extended
--------------------------------------------------------------------------------

- Net loss $23.9M ($0.44/sh) vs $39.5M ($0.73) in Q2 2022.
- Cash and marketable securities $151.5M; cash runway extended into Q4 2025 after restructuring.
- Interim GM1 data: PBGM01 well-tolerated; Dose 2 achieved normal CSF β-Gal activity and GM1 ganglioside levels durable to 12mo.
- First patient dosed at Dose 3 in July 2023; initial safety/biomarker data expected by mid-2024.
- FTD trial PBFT02: initial Cohort 1 data expected Q4 2023; six sites initiated in Brazil, Canada, US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/0001558370-23-013486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023013486/pasg-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer